Extended Spectrum Beta-Lactamase (ESBL) & Carbapenemase Producing Organisms (CPO) Antimicrobial importance
Our EasyScreen™ range of Antimicrobial resistance products are in-vitro nucleic acid amplification assays for the qualitative detection of ESBL and CPO pathogens.
Beta-lactam antibiotics are the most commonly used antibiotics worldwide for the treatment of bacterial infections. Extended Spectrum Beta-Lactamase (ESBL) producing organisms hydrolyse cephalosporins, penicillins and aztreonam, rendering them ineffective for treatment of infected patients. Carbapenem based antibiotics have become the first line choice in the treatment of ESBL infections. Of significant global concern therefor is the emergence of carbapenem resistant bacteria in healthcare settings, as standard treatments may be rendered ineffective. This makes accurate and timely detection of ESBL and Carbapenemase Producing Organisms (CPO) important as it will have a significant impact on patient management.
EasyScreen™ ESBL/CPO targets (BL001)
| Pan-CTX-M | Oxa-23 like | Oxa-51 like | Pan-CMY |
| GES | Pan-SHV | Vim2 | IMP |
| KPC | MCR-1 | IMI | NDM |
The kits also include both an Extraction Control and an Internal Positive Control for each sample to ensure the quality of the extracted DNA and to detect the presence of any inhibitors, respectively.
Regulatory
- The EasyScreen™ ESBL/CPO Detection Kit (BL001) is for in vitro diagnostic use
